BioAge Labs, Inc.
BIOA
Positions held
Your positionsBIOA isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $285.02M | Enterprise value | -$30.89M | Trailing P/E | — | Forward P/E | -2.57 |
| PEG | — | Price / book | 0.76 | Beta | 1.08 | Dividend yield | 0.00% |
| Revenue growth | 1.6% | Earnings growth | — | Gross margin | 0.0% | Operating margin | -12.0% |
| Profit margin | 0.0% | ROE | -28.2% | ROA | -18.5% | Debt / equity | 0.01 |
| Current ratio | 17.19 | Free cash flow | -$58.07M | Analyst recommendation | none | Mean target | $35.63 |
| 52w high | $25.96 | 52w low | $5.04 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $2.5M | $2.8M | $3.1M | $2.1M | $2.4M | — |
| Op margin | -1196.8% | -915.4% | -923.4% | -1126.6% | -1027.0% | — |
| Net income | -$26.1M | -$22.3M | -$25.9M | -$20.2M | -$21.6M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$29.3M | -$25.4M | -$28.4M | -$23.1M | -$24.8M | — |
- Revenue -12% vs prior quarter ($2.5M vs $2.8M).
- Operating margin compressed to -1196.8%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $9.0M | $0.0M | $0.0M | $0.0M |
| Op margin | -1031.5% | — | — | — |
| Net income | -$80.6M | -$71.1M | -$63.9M | -$39.7M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$92.8M | -$78.2M | -$48.4M | -$40.0M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-25 · BioAge Labs to Present at Upcoming Investor Conferences
2026-09-08 · BioAge Labs Doses First Patient in Phase 2 Trial of BGE-102 in Diabetic Macular Edema
2026-09-02 · BioAge Labs to Present at Upcoming Investor Conferences
2026-08-31 · Number of shares and votes in BioArctic AB (publ) as of August 31, 2026
2026-08-31 · Number of shares and votes in BioArctic AB (publ) as of August 31, 2026
2026-08-06 · BioAge Labs, Inc. (BIOA) Reports Q2 Loss, Beats Revenue Estimates
2026-08-05 · BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates
2026-07-31 · BIOA, GLUE Stocks Clock Worst Day In Years— What’s The NVO Connection?
Price (daily)
Full chart · RSI · MACD · patterns